Compare Cassava Sciences Inc (FLNA) vs Rockwell Automation (ROK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Rockwell Automation — how do they compare? Cassava Sciences Inc trades at $1.07 (market cap $53.14M), while Rockwell Automation trades at $464.26 (market cap $51.40B). The key difference: Rockwell Automation is far larger — about 967.3× Cassava Sciences Inc's market cap, and Rockwell Automation pays a 1.2% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | ROK | |
|---|---|---|
Market Cap | $53.14M | $51.40B |
Sector | Health | Industrials |
52-Week High | $4.64 | $495.08 |
52-Week Low | $1.09 | $328.67 |
Enterprise Value | -$33.43M | $55.03B |
Dividend Yield | — | 1.2% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Filana Therapeutics (FLNA) trades at $1.09, down 5.22% on the day, reflecting persistent operational losses despite recent earnings beats. The stock exhibits a strong bearish technical signal, with moving averages and oscillators aligned negatively. Fundamentally, the company is in a pre-revenue biotech development phase, evidenced by significant negative cash flow from operations (-$32.25M in 2025) and deeply negative profitability metrics (ROE: -79.59%). Recent news highlights continued focus on its Tuberous Sclerosis Complex (TSC)-related epilepsy program.
The outlook is bifurcated: a bullish analyst consensus (8 Buy, 4 Hold, 0 Sell) suggests optimism for the clinical pipeline, while severe financial burn and bearish technicals present substantial near-term risk. Investment opportunity hinges entirely on successful drug development, with significant dilution or financing risk as the company funds operations. The stock is suitable only for high-risk investors comfortable with binary clinical outcomes.
Rockwell Automation (ROK) trades at $469.77, up 2.02% today, with strong technical momentum and bullish moving average signals. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $3.30 exceeding estimates of $2.88. Revenue remains stable at $8.34B for 2025, though net income margin has declined to 10.41% from previous highs. Recent news highlights the company's leadership in industrial automation and AI integration.
ROK presents a mixed outlook with premium valuation metrics (P/E 47.97) offset by strong analyst support (30.77% buy ratings) and consistent dividend payments. Key risks include margin compression and competitive pressures in industrial automation. The consensus price target of $471.71 suggests limited near-term upside from current levels, requiring sustained earnings growth to justify valuation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Rockwell Automation
Rockwell Automation is a pure-play automation competitor that is the successor entity to Rockwell International, which spun off its former Rockwell Collins avionics segment in 2001. As of fiscal 2021, the firm operates through three segments--intelligent devices, software and control, and lifecycle services. Intelligent devices contains its drives, sensors, and industrial components, software and control contains its information and network and security software, while lifecycle services contains its consulting and maintenance services as well as its Sensia JV with Schlumberger.
Read more on ROK →
